Impact of Reperfusion on Clinical Outcomes in Patients with Intermediate-High Risk Pulmonary Embolism

•Mortality and prognosis of pulmonary embolism (PE) depend on clinical presentation and its proper stratification.•The benefit of pulmonary reperfusion (R) is still uncertain in intermediate-high risk PE, but a few new studies showed benefit with R•Of a cohort of intermediate-high PE patients, 16% received R treatment, either with systemic thrombolytics (89%), endovascular treatment (7%) or surgery (4%).•Bilateral PE, persistent dyspnea and age less than 70 years were independent predictors of R. There was a trend towards a reduction in mortality in R patients, without differences in total or major bleeding. This difference supports the indication of R according to current worldwide trends.